The worst performing department at Merck & Co., Inc. (NYSE:MRK) was Pharmaceutical, which saw revenue decline 12% from the previous year to $8.9 billion in the quarter. The saving grace was performance in the the emerging markets, which are proving to be an important market for Merck. In the last quarter, the region contributed approximately 21% to total pharmaceutical sales for the company. Sales in the region witnessed 6% year-on-year growth. The most prominent driver of growth was China.